વર્તમાન કિંમત
લક્ષ્ય કિંમત
વિશ્લેષક ભાવના
2 રેટિંગ્સ: ખરીદો
GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology. By addressing the underlying causes of diseases rather than...|
e.g. Promoter holding
Loading chart...
વિશ્લેષક સર્વસંમતિ EPS અને આવક અનુમાન.
| Metric (B) | FY 2025 | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 | FY 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-1.31 | $-1.11 | $-1.07 | $-3.74 | $-1.20 | $-0.84 | $-0.82 | $-2.03 | $-0.98 | $-2.00 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| -6.5% | -18.1% | -75.4% | +81.2% | +67.8% | +0.0% | +0.0% | +6.2% | +21.6% | +0.0% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TCara Thera... | TVRD | $15.74M | — | 1.87 | — | — | -126.20% | — |
| 2. | KKairos Pha... | KAPA | $1.54M | — | 0.37 | — | — | -114.00% | — |
| 3. | KKairos Pha... | KAPA | $1.54M | — | 0.37 | — | — | -114.00% | — |
| 4. | EPMGC Holdi... | ELAB | $1.28M | — | 0.08 | — | -470.00% | -105.20% | -45.80% |
| 5. | MMural Onco... | MURA | $35.38M | — | 0.64 | — | — | -103.90% | — |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Quarter (M) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 2.3 | 0 | 22.54 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 |
Gross Profit % | - | -0.04% | - | 0% | - | - | - | - |
| 2.13 | 1.95 | 3.05 | 2.9 | 3.37 | 2.66 | 2 | 2 | |
EBIT | -2.13 | -1.95 | -3.05 | -2.9 | -3.37 | -2.66 | -2 | -2 |
OPM % | - | -84.99% | - | -12.85% | - | - | - | - |
Non-Operating Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
PBT | -2.12 | -1.95 | -3.05 | -2.89 | -3.36 | -2.66 | -2 | -2 |
Income Tax | 0 | 0.65 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | -33.59% | - | - | - | - | - | - |
Net Income | -2.12 | -1.95 | -3.05 | -2.89 | -3.36 | -2.66 | -2 | -2 |
NPM % | - | -84.73% | - | -12.83% | - | - | - | - |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0.1 | 0 | 0 | 21.77 | 22.54 | 0 |
COGS | 0 | 0 | 0.1 | 0.07 | 0.21 | 0.06 | 11.63 | 0 |
Gross Profit | -0 | -0 | 0.1 | -0.07 | -0.21 | 21.71 | 10.91 | -0 |
Gross Profit % | - | - | 100% | - | - | 99.74% | 48.41% | - |
| 4.31 | 3.15 | 4.81 | 1.06 | 2.24 | 11.39 | 8.23 | 11.98 | |
EBIT | -4.31 | -3.15 | -4.79 | -1.06 | -2.24 | -11.39 | -8.23 | -11.98 |
OPM % | - | - | -4788% | - | - | -52.31% | -36.54% | - |
Non-Operating Income | 0 | 0 | -0.03 | -0.5 | -0.98 | -1.65 | 0.03 | 0.02 |
PBT | -4.31 | -3.46 | -4.82 | -1.56 | -3.22 | -13.04 | -8.21 | -11.96 |
Income Tax | -0 | 0 | -0.13 | -0.05 | 0.33 | 2.77 | 0 | 0 |
Tax Rate % | 0% | 0% | 2.72% | 3.21% | -10.1% | -21.21% | - | - |
Net Income | -4.31 | -3.46 | -4.82 | -1.56 | -3.22 | -13.04 | -8.21 | -11.96 |
NPM % | - | - | -4822% | - | - | -59.89% | -36.41% | - |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| 0.61 | 3.82 | 0.11 | 3.7 | 0.01 | 1.81 | 5.03 | 8.23 | |
| 0 | 0 | 0 | 3.81 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0.02 | 0.1 | 0.56 | 0.62 | 0.3 | 1.13 | 0.59 | 0.36 | |
| 0 | 0.35 | 0.28 | 0.21 | 0.07 | 0.02 | 0.12 | 0.07 | |
Total Assets | 0.64 | 4.28 | 0.95 | 8.34 | 0.38 | 2.96 | 5.74 | 8.67 |
| 0.01 | 0.02 | 0 | 0.35 | 0 | 0 | 0 | 0 | |
| 0.14 | 3.2 | -1.45 | 5.47 | -1.63 | 0.26 | 4.03 | 6.01 | |
| 0 | 0.34 | 0.34 | 0.17 | 0.67 | 0.01 | 0.12 | 0.07 | |
| 0.49 | 0.72 | 1.99 | 2.29 | 1.39 | 2.68 | 1.54 | 2.53 | |
| 0 | 0 | 0.08 | 0.06 | -0.05 | 0 | 0.05 | 0.06 | |
Total Liabilities | 0.64 | 4.28 | 0.95 | 8.34 | 0.38 | 2.96 | 5.74 | 8.67 |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| -2.37 | -2.88 | -3.71 | -8.31 | -1.08 | -9.14 | -8.61 | -10.19 | |
| -0 | 0 | -0 | -3.84 | -0 | -0.01 | 0 | -0 | |
| 2.99 | 6.09 | -0 | 15.75 | 1.01 | 10.95 | 11.83 | 13.39 | |
Net CFNet Cash Flow | 0.61 | 3.21 | -3.71 | 3.59 | -0.08 | 1.8 | 3.22 | 3.2 |
FCFFree Cash Flow | -2.37 | -2.88 | -3.71 | -8.31 | -1.09 | -9.15 | -8.61 | -10.19 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| - | -205.8% | -548.0% | -71.4% | -153.4% | 1908.8% | -382.5% | -238.2% | |
| - | 0.11 | -0.23 | 0.03 | -0.41 | 0.05 | 0.03 | 0.01 | |
| 1.31 | 4.86 | 0.30 | 3.32 | 0.16 | 1.09 | 3.43 | 3.25 | |
| - | - | 0.04 | 0.00 | 0.00 | 13.04 | 5.18 | 0.00 | |
Cash Conversion | 0.55 | 0.83 | 0.77 | 5.33 | 0.34 | 0.70 | 1.05 | 0.85 |
Payout Ratio | - | - | - | - | - | - | - | - |
| - | - | - | -100.0% | - | - | 3.5% | -100.0% | |
| -0.96 | -0.77 | -1.07 | -0.23 | -0.25 | -3.16 | -2.60 | -3.78 | |
| - | - | - | -1574509.97 | -52161.83 | -159.91 | -5.94 | -0.08 | |
| 3.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 3.00 | 3.00 | |
| - | - | - | - | - | - | -0.49 | - | |
| 0.00 | 50.00 | 100.00 | 50.00 | - | 66.67 | 60.00 | 50.00 | |
| - | - | -48.2% | - | - | -0.6% | -0.4% | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
GRI Bio Inc ની માલિકી કોની પાસે છે, SEC ફાઇલિંગ્સ મુજબ
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| % of shares outstanding | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
InsidersInsiders | 23.13% | 25.26% | 8.28% | 138.93% | 138.93% | 0.00% | 0.00% | 0.00% | 0.00 |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.49% | 0.23% | -0.26 | |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.10% | 4.05% | +2.95 | |
Govt.Government & pensions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
Public | 76.87% | 74.74% | 91.72% | 0.00% | 0.00% | 99.99% | 98.41% | 95.72% | -2.69 |
No. of institutional holders | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 11 | +5 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Investment adviser | NJ | 159,378 | 7.30% | SC 13G · 12 Nov 2026 | |
| Holding company | X1 | 93,005 | 4.99% | SC 13G/A · 13 Aug 2026 | |
| Other | DE | 0 | 0.00% | SC 13G/A · 10 Feb 2026 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | % of shares out | Days to cover | Relative size |
|---|---|---|---|---|---|
| 30 Oct 2026 | 66,510 | +0.6% | 3.04% | 1.56 | |
| 15 Oct 2026 | 66,115 | -4.8% | 3.02% | 1.62 | |
| 30 Sep 2026 | 69,429 | -40.7% | 3.18% | 1.00 | |
| 15 Sep 2026 | 117,104 | -0.3% | 5.36% | 1.00 | |
| 31 Aug 2026 | 117,514 | -7.5% | 5.38% | 1.50 | |
| 14 Aug 2026 | 127,075 | +15.5% | 5.81% | 1.00 | |
| 31 Jul 2026 | 110,031 | -12.7% | 5.03% | 4.45 | |
| 15 Jul 2026 | 126,073 | +9.7% | 5.77% | 2.79 | |
| 30 Jun 2026 | 114,892 | -14.4% | 5.26% | 1.00 | |
| 15 Jun 2026 | 134,230 | +8.7% | 6.14% | 2.03 | |
| 29 May 2026 | 123,491 | +8.3% | 5.65% | 3.76 | |
| 15 May 2026 | 114,067 | +6.2% | 5.22% | 3.58 | |
| 30 Apr 2026 | 107,369 | -20.1% | 4.91% | 2.29 | |
| 15 Apr 2026 | 134,378 | +19.5% | 6.15% | 1.00 | |
| 31 Mar 2026 | 112,439 | +6.5% | 5.14% | 3.47 | |
| 13 Mar 2026 | 105,615 | -21.9% | 4.83% | 2.24 | |
| 27 Feb 2026 | 135,157 | -13.6% | 6.18% | 2.27 | |
| 13 Feb 2026 | 156,438 | +5.7% | 7.16% | 1.00 | |
| 30 Jan 2026 | 148,008 | -78.9% | 6.77% | 1.00 | |
| 15 Jan 2026 | 700,747 | -73.9% | 32.05% | 1.00 | |
| 31 Dec 2025 | 2,686,135 | +600.2% | 122.87% | 1.00 | |
| 15 Dec 2025 | 383,633 | +169.5% | 17.55% | 1.00 | |
| 28 Nov 2025 | 142,328 | +18.8% | 6.51% | 1.00 | |
| 14 Nov 2025 | 119,760 | -40.4% | 5.48% | 1.01 |
FINRA consolidated short interest, reported twice a month for every US listing.
GRI Bio Inc ના SEC ફાઇલિંગ્સ અને અર્નિંગ્સ કૉલ ટ્રાન્સક્રિપ્ટ્સ
What recent news says about GRI Bio Inc, scored for sentiment.